Paulus, W., Hermsteiner, E., Haug, B., & Bandelow, B. . It may take up to 1-5 minutes before you receive it. . Investigation of RGS2 and RGS13 gene polymorphisms in human panic disorder (Poster abstract). Mara Parellada, As a specialist for psychiatry and neurology, a psychologist, and a psychotherapist, Dr. Bandelow specializes mainly in the field of anxiety disorders, but also in depression, schizophrenia, psychotherapy and psychopharmacology. (Ed. Angst – Neurobiologie. (1997). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – first revision. (2013a). In B. Bandelow (Ed. Die Behandlung von Angsterkrankungen mit Clomipramin – eine Analyse von Kasuistiken. Bandelow, B.

Drug treatment of generalized anxiety disorder (GAD) – a consensus statement. Passie, T., Schneider, U., Borsutzky, M., Breyer, R., Emrich, H. M., Bandelow, B., & Schmid-Ott, G. (2013). Domschke, K., Hohoff, C., Jacob, C., Maier, W., Fritze, J., Bandelow, B., . In D. Stein & B. Vythilingum (Eds. Möller (Ed.

Bandelow, B. [The social status of schizophrenic patients]. Helen Fisher, Bandelow, B., Engel, K., Wedekind, D., & Amberger, S. Neurotische, somatoforme und Belastungsstörungen : Angststörungen. Soziale Phobie – Medikamentöse und psychotherapeutische Verfahren und Kombinationstherapie im Vergleich. Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. (1996). Depressive syndromes in schizophrenic patients under neuroleptic therapy. Increment Threshold and Postadaptation Threshold Are Increased in Parkinsons-Disease. Panic disorder during pregnancy and postpartum period. Increased psychobehavioral responsiveness to M-chlorophenylpiperazine (m-CPP) and ipsapirone (IPS) in patients with panic disorder (PDA). In H.-J. . He is married to Gabriele. Ruther, E. (1998). Kornhuber, J. Bandelow, B., Wiltink, J., Alpers, G. W., Benecke, C., Deckert, J., Eckhardt-Henn, A., . Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. [Guideline-oriented inpatient psychiatric psychotherapeutic/psychosomatic treatment of anxiety disorders : How many personnel are need?]. Bandelow, B., Zohar, J., Kasper, S., & Moller, H. J. Fetal alcohol exposure and adult psychiatric disorders – Dr. Broocks and Bandelow reply. . Meyer, T., Broocks, A., Bandelow, B., Hillmer-Vogel, U., & Ruther, E. (1998). (2009). Soziale Phobie – Medikamentöse Therapie. Improvement of quality of life in panic disorder with escitalopram, citalopram, or placebo. . Bandelow, B., & Broocks, B. A 2010 evidence-based algorithm for the pharmacotherapy of social anxiety disorder. Psychiatrische Notfälle. (2010a). (2013). Bandelow, B. Angsterkrankungen – Panikstörung, soziale und generalisierte Angststörung. Wolff-Menzler, C., & Bandelow, B. RGS2 ggenetic variation: association analysis with panic disorder and dimensional as well as intermediate phenotypes of anxiety. Stein, D., Kalali, A., Bandelow, B., Katzman, M. A., Olausson, B., & Eriksson, H. (2010). ANI Study Group Berlin, Dusseldorf, Gottingen, Munich, Federal Republic of Germany. . World Council of, A. BORDERLINE PERSONALITY DISORDER – A DYSREGULATION OF THE ENDOGENOUS OPIOID SYSTEM? Bandelow, B., & Haug, T. T. (2004). Bandelow B (1995): Assessing the efficacy of treatments for panic disorder and agoraphobia. Bandelow, B.

The role of environmental factors in the etiology of social anxiety disorder. Bandelow, B., & Ruther, E. (2004). A new pharmaceutical target for psychiatry and neurology].

Comparison of the DSM-5 and ICD-10: panic and other anxiety disorders. [Recommendations for the use of measuring instruments in clinical anxiety research]. Int Clin Psychopharmacol 30:183-92.Bandelow B, Baldwin D, Abelli M, et al (2017a): Biological markers for anxiety disorders, OCD and PTSD: A consensus statement.